Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

Francisco Cervantes, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian et al. · Blood · 2013 · 425 citations · Full text

Medicine, Hematology, Pharmacology +4

Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634

Christel Menet, Stephen R. Fletcher, Guy Van Lommen et al. · Journal of Medicinal Chemistry · 2014 · 121 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis

Martin E. Dowty, Michael I. Jesson, Sarbani Ghosh et al. · Journal of Pharmacology and Experimental Therapeutics · 2013 · 116 citations

Medicine, Pharmacokinetics, Pharmacology +14

Comprehensive review of JAK inhibitors in myeloproliferative neoplasms

Mohamad Bassam Sonbol, Belal Firwana, Ahmad Zarzour et al. · Therapeutic Advances in Hematology · 2012 · 99 citations · Full text

Medicine, Hematology, Pharmacology +17

<i>N</i>-Amination of Pyrrole and Indole Heterocycles with Monochloramine (NH₂Cl)

John Hynes, Wendel W. Doubleday, Alaric J. Dyckman et al. · The Journal of Organic Chemistry · 2004 · 80 citations

Natural Sciences, Chemistry, Medicinal Chemistry +10